Intra-annular fibrin injection works because fibrin functions as a biologic scaffold. Delivered into an annular tear under fluoroscopic guidance, the fibrin matrix holds the tear closed, supports cell migration into the lesion, and creates conditions for the body’s own healing response to close the tear over weeks to months.
Key Takeaways
- Fibrin is a naturally-occurring protein; the sealant is FDA-approved.
- The mechanism is reparative — the fibrin scaffolds tissue healing.
- Imaging guidance ensures placement within the tear itself.
- Healing continues for several months after placement.
- The procedure does not regrow lost disc height or restore end-stage discs.
What This Guide Covers
- What is fibrin?
- How does scaffolding work in tissue?
- What is special about the disc context?
- What does the evidence base look like?
What is fibrin?
Fibrin is a naturally-occurring protein that the body produces during clotting and tissue repair. The fibrin sealant used in the procedure is FDA-approved and has a long history of clinical use across surgical fields. In the spine context, the sealant is delivered into the annular tear and functions as a biologic scaffold for tissue healing.
How does scaffolding work in tissue?
A scaffold provides physical structure that cells migrate into. In a healing wound, fibrin holds the tissue edges in apposition while cells lay down new collagen and other matrix proteins. In the disc, the same principle applies: fibrin holds the annular tear closed and gives cells a structure to populate as they rebuild the annulus.
What is special about the disc context?
The disc has limited blood supply, which makes intrinsic healing slow. Delivering fibrin directly into the lesion concentrates the scaffolding effect at the site that needs it most. The fluoroscopic guidance ensures the sealant reaches the tear rather than dispersing into adjacent structures.
What does the evidence base look like?
The procedure has been performed more than 13,000 times nationally, with 7,000+ patients tracked through long-term follow-up showing an 83% success rate. Patient-reported VAS pain scores in published cohorts moved from a 72.4mm baseline to 33.0mm at 104 weeks. Patient satisfaction at two-plus years has been reported at 70%. Among the most-tracked outcomes, individual results vary.
Clinical Note
The “science” of the procedure sometimes gets oversold in marketing materials. Our clinical staff describes it precisely: fibrin is a natural protein, the sealant is FDA-approved, and the mechanism is well-understood biology — scaffolding for tissue repair. None of this is novel chemistry. What is newer is the application: targeting fibrin directly into annular tears under imaging guidance. The Valor team treats the science as a starting point for a candidacy conversation, not as a sales argument. Patients who understand the mechanism tend to make better-informed decisions about whether the procedure fits their case.
Frequently Asked Questions
Is fibrin the same as platelet-rich plasma (PRP)?
No. Fibrin is a specific protein scaffold; PRP is concentrated platelets. Different mechanisms, different applications.
Will my body reject the fibrin?
Fibrin is a natural protein the body recognizes. Rejection is not a typical concern.
Does the fibrin stay in place permanently?
The fibrin matrix integrates into healing tissue over time. The scaffold is gradually replaced by the body’s own repair tissue.
Related reading:
This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified physician. Treatment decisions depend on your individual medical history and clinical findings. Schedule a consultation to discuss whether the procedure is right for you.
